Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Anika Therapeutics (ANIK)

Anika Therapeutics (ANIK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 820,182
  • Shares Outstanding, K 14,269
  • Annual Sales, $ 105,560 K
  • Annual Income, $ 18,720 K
  • 60-Month Beta 0.99
  • Price/Sales 7.71
  • Price/Cash Flow 24.82
  • Price/Book 2.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.41
  • Number of Estimates 2
  • High Estimate 0.43
  • Low Estimate 0.38
  • Prior Year 0.54
  • Growth Rate Est. (year over year) -24.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.14 +4.24%
on 12/03/19
61.43 -6.43%
on 11/07/19
-3.00 (-4.96%)
since 11/06/19
3-Month
51.02 +12.65%
on 09/23/19
75.71 -24.08%
on 10/25/19
+2.28 (+4.13%)
since 09/06/19
52-Week
29.01 +98.14%
on 03/27/19
75.71 -24.08%
on 10/25/19
+25.34 (+78.84%)
since 12/06/18

Most Recent Stories

More News
Sage Therapeutics' Depression Drug Fails in Study, Stock Down

Sage Therapeutics' (SAGE) phase III study on pipeline candidate SAGE-217 for the treatment of major depressive disorder fails to meet the primary endpoint.

ANIK : 57.48 (+0.75%)
ALKS : 20.95 (+1.45%)
SAGE : 64.46 (+7.11%)
VTGN : 0.44 (unch)
Cosmetic Procedures Market (2020-2029) SWOT Analysis by Leading Key Players | Allergan, Johnson & Johnson Services, GC Aesthetics

“A Precise market analysis on Global | Know Up Trends And More About Industry Tycoons, Emerging Growth Factors, Opportunities, Top Key Players, Target Audience, Capital Investment Status, Production,...

AGN : 186.37 (+0.16%)
ANIK : 57.48 (+0.75%)
HOLX : 52.74 (+0.88%)
ELOS : 11.00 (unch)
VRX.TO : 30.80 (-3.33%)
Spero Posts Preliminary Data on SPR720 for Pulmonary Disease

Spero (SPRO) reports preliminary findings from a phase I first-in-human study on SPR720, presently being evaluated for the treatment of nontuberculous mycobacterial pulmonary disease.

VRTX : 223.25 (+0.08%)
ANIK : 57.48 (+0.75%)
GH : 73.98 (+0.54%)
SPRO : 11.94 (+4.46%)
Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug

Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.

ALKS : 20.95 (+1.45%)
INVA : 12.91 (-0.46%)
ANIK : 57.48 (+0.75%)
RARX : 47.00 (+0.36%)
Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon

Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.

ANIK : 57.48 (+0.75%)
ALKS : 20.95 (+1.45%)
BDSI : 6.43 (-0.92%)
ZEAL : 32.87 (+5.83%)
Biogen's Lupus Candidate Meets Endpoint in Phase II Study

Biogen (BIIB) posts favorable top-line results from a phase II study evaluating BIIB059 for treating cutaneous and systemic lupus erythematosus. The study tastes success by achieving its main goal.

AZN : 47.68 (+0.13%)
ANIK : 57.48 (+0.75%)
BIIB : 300.26 (+0.29%)
VRTX : 223.25 (+0.08%)
Seattle Genetics, Astellas Tie Up With Merck for Cancer Study

Seattle Genetics (SGEN) and Astellas team up with Merck for a late-stage study to evaluate the enfortumab vedotin and Keytruda combo in patients with previously untreated metastatic urothelial cancer.

MRK : 88.85 (+0.11%)
SGEN : 117.50 (+0.29%)
VRTX : 223.25 (+0.08%)
ANIK : 57.48 (+0.75%)
Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU

The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.

BDSI : 6.43 (-0.92%)
AMRN : 22.45 (+2.93%)
ALKS : 20.95 (+1.45%)
ANIK : 57.48 (+0.75%)
Puma Biotech Expands Pierre Fabre License to Add Countries

Puma Biotech (PBYI) stretches its license deal with Pierre Fabre, granting the latter commercial rights to Nerlynx in new countries across Europe and parts of Africa. Stock rallies.

RHHBY : 38.5700 (+0.36%)
VRTX : 223.25 (+0.08%)
PBYI : 7.88 (+5.91%)
ANIK : 57.48 (+0.75%)
Acorda (ACOR) Down More Than 80% Year to Date: Here's Why

Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States, which is hurting the company's top line of late. Parkinson's disease drug Inbrija seems an ideal replacement.

ACOR : 1.71 (+0.59%)
VRTX : 223.25 (+0.08%)
ANIK : 57.48 (+0.75%)
MYL : 19.29 (+2.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ANIK with:

Business Summary

Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative...

See More

Key Turning Points

2nd Resistance Point 59.46
1st Resistance Point 58.47
Last Price 57.48
1st Support Level 56.75
2nd Support Level 56.02

See More

52-Week High 75.71
Fibonacci 61.8% 57.87
Last Price 57.48
Fibonacci 50% 52.36
Fibonacci 38.2% 46.85
52-Week Low 29.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar